SCHEMBL3863769

SCHEMBL3863769

CSC[C@@H](C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL550594 1.00
SCHEMBL550638 1.00
Hydrochloric Acid SCHEMBL15422026 0.96
Hydrochloric Acid SCHEMBL629821 0.96
Hydrochloric Acid SCHEMBL629822 0.96
SCHEMBL14615682 0.81
SCHEMBL6904890 0.77 TSHR (0.50)
SCHEMBL15702330 0.77 TSHR (0.50)
SCHEMBL4100101 0.72 ANPEP (0.47)
SCHEMBL13448317 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119161334-A Amide derivative containing thiophene structure, preparation method and application thereof 贵州大学 2024-12-20 CN claimed
CN-119161334-A Amide derivative containing thiophene structure, preparation method and application thereof 贵州大学 2024-12-20 CN disclosed
CN-113248497-B Fused ring derivatives useful as FGFR4 inhibitors 北京加科思新药研发有限公司 2022-08-19 CN disclosed
US-20220119386-A1 FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR JACOBIO PHARMACEUTICALS CO LTD (CN) 2022-04-21 US disclosed
US-11299457-B2 Chemical compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-04-12 US disclosed
US-11136320-B2 Fused ring derivative used as FGFR4 inhibitor JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-10-05 US disclosed
CN-113248497-A Fused ring derivatives useful as FGFR4 inhibitors 北京加科思新药研发有限公司 2021-08-13 CN disclosed
EP-3831827-A1 FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR Jacobio Pharmaceuticals Co., Ltd. (CN) 2021-06-09 EP disclosed
US-20210163478-A1 FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR JACOBIO PHARMACEUTICALS CO., LTD (CN) 2021-06-03 US disclosed
US-11001556-B2 Crystalline forms GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-05-11 US disclosed
US-7601726-B2 Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-10-13 US disclosed
US-7601726-B2 Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-10-13 US disclosed
US-7601726-B2 Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-10-13 US disclosed
WO-2008068171-A9 SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS HOFFMANN LA ROCHE (CH) 2009-07-16 WO disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed
WO-2008068171-A1 SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed
US-20070054915-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-03-08 US disclosed
US-20070054915-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-03-08 US disclosed
US-20070054915-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-03-08 US disclosed
WO-2007023110-A2 P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 WO disclosed